Compare FedEx Corporation (FDX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs 10X Genomics Inc — how do they compare? FedEx Corporation trades at $291.66 (market cap $69.04B), while 10X Genomics Inc trades at $80.87 (market cap $10.07B). The key difference: FedEx Corporation is far larger — about 6.9× 10X Genomics Inc's market cap, and FedEx Corporation pays a 1.67% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and 10X Genomics Inc for 91 Days on average.
| FDX | TXG | |
|---|---|---|
Market Cap | $69.04B | $10.07B |
Volume | 1,287,367 | 5,657,286 |
Sector | Industrials | Health |
52-Week High | $339.35 | $97.74 |
52-Week Low | $180.87 | $11.48 |
Typical Hold Time | 87 Days | 91 Days |
Enterprise Value | $98.68B | $9.59B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.71, up 0.92% today, with a bearish technical signal but strong fundamentals including a P/E of 15.73 and net income margin of 4.68%. Recent Q1 2026 earnings beat expectations at $6.31 EPS. The company announced a $300 million electric truck order from Harbinger (TechCrunch, 2026-09-30) and a $1.22 dividend payable October 1, 2026. Cash flow from operations was $7.04B in 2025, with a projected rebound to $8.9B in 2026.
The outlook is mixed: analyst consensus is a Buy with a $307.55 price target, but rising fuel costs and geopolitical tensions pose margin risks. Earnings growth and cost-cutting initiatives support upside, while technical resistance near $294 may limit near-term gains. Debt-to-asset ratio is expected to rise to 25.99% in 2026, adding financial leverage concerns.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
